account_id none on file
legal_name SAB Biotherapeutics, Inc.
ticker SABS
cik 1833214
domain sab.bio
linkedin_company_url https://www.linkedin.com/company/sab-biotherapeutics/
entry_point_account_id none on file
name SAB Biotherapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 14 executives 0 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses increased by $4.5 million or 163.4%, in the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, primarily due to increased headcount costs, including related stock based compensation.
filing / Aug 6, 2026 / receipt
General and administrative expenses increased by $8.0 million, or 136.0%, in the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, primarily due to increased headcount costs, including related stock based compensation.
filing / Aug 6, 2026 / receipt
We terminated our office lease in Miami Beach, Florida and entered into a new lease for expanded space at the same location.
filing / Aug 6, 2026 / receipt
The Company entered into a lease for office space in Miami Beach, Florida in April 2024. In September 2025, the Company terminated this lease and entered into a new lease for expanded space.
filing / Aug 6, 2026 / receipt
Based on the evaluation as of June 30, 2026, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2026.
filing / Aug 6, 2026 / receipt
General and administrative expenses increased by $4.5 million or 163.4%, in the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, primarily due to increased headcount costs, including related stock based compensation.
filing / Aug 6, 2026 / receipt
General and administrative expenses increased by $8.0 million, or 136.0%, in the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, primarily due to increased headcount costs, including related stock based compensation.
filing / Aug 6, 2026 / receipt
We terminated our office lease in Miami Beach, Florida and entered into a new lease for expanded space at the same location.
filing / Aug 6, 2026 / receipt
The Company entered into a lease for office space in Miami Beach, Florida in April 2024. In September 2025, the Company terminated this lease and entered into a new lease for expanded space.
filing / Aug 6, 2026 / receipt
Based on the evaluation as of June 30, 2026, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2026.
filing / Aug 6, 2026 / receipt
In April 2024, the Company entered into a lease for 1,272 square feet of office space in Miami Beach, Florida. The initial term was 62 months, with monthly payments of approximately $ 7 thousand through 2024 and annual escalations of 4 % through 2029.
filing / May 12, 2026 / receipt
Based on the evaluation as of March 31, 2026, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2026.
filing / May 12, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug sab-biotherapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$